Indeed, the authorsclaimed that FGFR inhibition by 54 might regulate differentchaperones involved in F508del-CFTR maturation, as evinced from chaperonearray analysis.157 However, 54 exhibits significant off-target activities, such as the inhibitionof several tyrosine kinases different from FGFR1.215 Thus, 54 is far from having a possible therapeuticvalue for the treatment of CF, and the development of more specificand potent analogues is pivotal for further investigations. The gene discussed is CFTR; the disease is cystic fibrosis.